Literature DB >> 31848682

Factors affecting quality of life in patients with hidradenitis suppurativa.

Astrid-Helene Ravn Jørgensen1, Jesper Grønlund Holm2, Misbah Noshela Ghazanfar2, Yiqiu Yao2, Hans Christian Ring2, Simon Francis Thomsen2,3.   

Abstract

Hidradenitis suppurativa (HS) has a substantial impact on patients' lives. We identified factors associated with decreased quality of life (QoL) in patients with HS. Consecutive newly referred patients with HS attending a tertiary referral centre for HS were evaluated with the dermatology life quality index (DLQI). Clinical evaluation was performed according to the Hurley stage. Furthermore, disease duration, number of boils in the past month, boil-associated pain score, overall disease-related distress score, smoking status, employment status and comorbidities were recorded. A total of 339 patients with a mean age of 39.4 years were included; 218 (64.3%) females and 121 (35.7%) males. Of these, 96 (28.3%) had Hurley stage I, whereas 195 (57.5%) and 48 (14.2%) had Hurley II and III, respectively. The mean BMI was 29.0 (SD 7.1) kg/m2 and 75.2% of patients were current or former smokers. The mean overall DLQI score was 11.9 (SD 7.6). After mutual adjustment for clinical characteristics a significant difference in mean overall DLQI score was observed between severity groups (8.6 vs. 12.6 vs. 16.1, adjusted p < 0.001, for Hurley I, II and III, respectively), age group (12.1 vs. 12.1 vs. 12.5 vs. 7.1, adjusted p = 0.002, for ≤ 20, 21-40, 41-60 and > 60 years, respectively), employment status (11.0 vs. 14.6, adjusted p = 0.003, for employed and unemployed, respectively), presence of boils in the preceding month (8.3 vs. 13.6, adjusted p = 0.001, for no boils and presence of boils, respectively), higher overall disease-related distress score (6.3 vs. 13.9, adjusted p < 0.001, for low and high score, respectively), involvement of the groins (8.7 vs. 13.0, adjusted p = 0.035 for no and involvement, respectively), high number of anatomical regions involved (9.8 vs. 12.4 vs. 14.5, adjusted p = 0.007 for 0-1, 2 and ≥ 3 anatomical regions involved, respectively) and diabetes (11.5 vs. 15.2, adjusted p = 0.043, for no and diabetes, respectively). All ten individual DLQI question scores increased significantly with increasing Hurley stage. Patients with HS referred for specialized hospital care report substantial impact on the quality of life. Disease severity (Hurley stage), younger age, diabetes, recent and increasing disease activity and specific anogenital localization are major aggravating factors.

Entities:  

Keywords:  Hidradenitis suppurative; Quality of life

Year:  2019        PMID: 31848682     DOI: 10.1007/s00403-019-02025-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  11 in total

1.  Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study.

Authors:  M M Shinohara; H M Mahurin; E Tarabadkar; D S Hippe; K Lachance; E J Kim; E T Loggers
Journal:  Skin Health Dis       Date:  2021-05-15

2.  Overall Impairment of Quality of Life in Japanese Patients with Hidradenitis Suppurativa: Comparison with National Standard.

Authors:  Koremasa Hayama; Hideki Fujita; Takashi Hashimoto; Tadashi Terui
Journal:  Acta Derm Venereol       Date:  2022-01-18       Impact factor: 3.875

3.  Treatment Patterns of Atopic Dermatitis Medication in 0-10-Year-Olds: A Nationwide Prescription-Based Study.

Authors:  Cathrine Helene Mohn; Hege S Blix; Anja Maria Brænd; Per Nafstad; Ståle Nygard; Jon Anders Halvorsen
Journal:  Dermatol Ther (Heidelb)       Date:  2022-06-28

4.  Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients.

Authors:  Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat
Journal:  Front Med (Lausanne)       Date:  2021-04-27

5.  Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients.

Authors:  Piotr K Krajewski; Łukasz Matusiak; Esther von Stebut; Michael Schultheis; Uwe Kirschner; Georgios Nikolakis; Jacek C Szepietowski
Journal:  Life (Basel)       Date:  2021-01-08

6.  The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa.

Authors:  Alex Bató; Valentin Brodszky; L Hunor Gergely; Krisztián Gáspár; Norbert Wikonkál; Ágnes Kinyó; Ákos Szabó; Zsuzsanna Beretzky; Andrea Szegedi; Éva Remenyik; Norbert Kiss; Miklós Sárdy; Fanni Rencz
Journal:  Qual Life Res       Date:  2021-02-03       Impact factor: 4.147

7.  Quality of Life of Patients With Hidradenitis Suppurativa in Jeddah, Saudi Arabia.

Authors:  Awadh M Alamri; Abeer A Alzahrani; Anan M Aldakhil; Heba E Alharbi; Farah A Yahya
Journal:  Cureus       Date:  2021-12-07

8.  Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.

Authors:  Afsaneh Alavi; Iltefat Hamzavi; Kurt Brown; Leandro L Santos; Zhaoyin Zhu; Huiqing Liu; Michael D Howell; Joslyn S Kirby
Journal:  Br J Dermatol       Date:  2022-03-06       Impact factor: 11.113

Review 9.  Quality of Life in Hidradenitis Suppurativa: An Update.

Authors:  Pavel V Chernyshov; Andrew Y Finlay; Lucia Tomas-Aragones; Francoise Poot; Francesca Sampogna; Servando E Marron; Sergey V Zemskov; Damiano Abeni; Thrasyvoulos Tzellos; Jacek C Szepietowski; Christos C Zouboulis
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

10.  Irrelevance of Panton-Valentine leukocidin in hidradenitis suppurativa: results from a pilot, observational study.

Authors:  Monica Corazza; Alessandro Borghi; Vincenzo Bettoli; Roberto Pora; Ilaria Bononi; Elisa Mazzoni; Elisa Mazzola; Silva Saraceni; Martina Maritati; Carlo Contini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.